| DC-CIK联合化疗加靶向治疗对晚期结肠癌的临床疗效观察 |
| |
| 引用本文： | 陈 芬1,' target='_blank'>2,江千秋1,' target='_blank'>3,焦 兰4,贺 颖1,' target='_blank'>2,翟福林1,' target='_blank'>2,欧利芳1,' target='_blank'>2. DC-CIK联合化疗加靶向治疗对晚期结肠癌的临床疗效观察[J]. 现代肿瘤医学, 2015, 0(12): 1686-1690. DOI: 10.3969/j.issn.1672-4992.2015.12.17 |
| |
| 作者姓名： | 陈 芬1 ' target='_blank'>2 江千秋1 ' target='_blank'>3 焦 兰4 贺 颖1 ' target='_blank'>2 翟福林1 ' target='_blank'>2 欧利芳1 ' target='_blank'>2 |
| |
| 作者单位： | 1.南华大学转化医学研究所，湖南 郴州 423000；2.郴州市第一人民医院肿瘤科;3.药剂科，湖南 郴州 423000；4.南华大学附属第一医院急诊科，湖南 衡阳 421001 |
| |
| 基金项目： | 郴州市第一人民医院科研项目（编号:N2012-019）；湘南学院科学研究项目（编号:2012-037） |
| |
| 摘 要： | 目的:观察DC-CIK联合化疗加靶向治疗治疗晚期结肠癌的疗效及安全性。方法:选取晚期结肠癌患者，DC-CIK联合化疗加靶向治疗（奥沙利铂+卡培他滨+贝伐单抗）为联合治疗组(30例)，同期进行化疗加靶向治疗(奥沙利铂+卡培他滨+贝伐单抗)的晚期结肠癌患者为化疗加靶向治疗组(30例)，比较两组患者治疗后的免疫功能、近期疗效、1年生存率、生活质量，并观察DC-CIK细胞治疗的安全性。结果:成功培养患者的DC-CIK细胞，其中CD3+CD8+、CD3+CD56+细胞比例较培养前显著提高(P＜0.05)。与化疗加靶向治疗组相比，联合治疗组患者治疗后外周血细胞CD3+CD8+、CD3+CD56+细胞比例明显升高(P＜0.05)。与治疗前相比，联合治疗组患者治疗后T细胞分泌IFN-γ、IL-2水平显著升高(P＜0.05)。化疗加靶向治疗组患者治疗后外周血各T细胞亚群比例和T细胞分泌IFN-γ、IL-2水平较治疗前降低，但均无统计学差异(P＞0.05)。联合治疗组患者的疾病控制率显著高于化疗加靶向治疗组(86% vs 60%，P＜0.01)。联合治疗组患者1年生存率与化疗加靶向治疗组比较无统计学差异(62% vs 56%，P＞0.05)。治疗后毒副反应(包括骨髓抑制、恶心呕吐、周围神经毒性)联合治疗组明显轻于化疗加靶向治疗组(P＜0.05)，治疗后体力食欲改善明显(P＜0.05)。结论:与化疗加靶向治疗组相比，DC-CIK联合化疗加靶向治疗治疗晚期结肠癌安全有效，可以提高缓解率，延长生存期，改善患者的生活质量。
|
| 关 键 词： | DC-CIK 晚期结肠癌 过继免疫细胞治疗 靶向治疗 化疗 |
Dendritic cell-cytokine induced killer cells combined with chemotherapy and targeted therapy in treatment of advanced colon cancer patients |
| |
| Chen Fen1,' target='_blank'>2,Jiang Qianqiu1,' target='_blank'>3,Jiao Lan4,He Ying1,' target='_blank'>2,Zhai Fulin1,' target='_blank'>2,Ou Lifang1,' target='_blank'>2. Dendritic cell-cytokine induced killer cells combined with chemotherapy and targeted therapy in treatment of advanced colon cancer patients[J]. Journal of Modern Oncology, 2015, 0(12): 1686-1690. DOI: 10.3969/j.issn.1672-4992.2015.12.17 |
| |
| Authors: | Chen Fen1 ' target='_blank'>2 Jiang Qianqiu1 ' target='_blank'>3 Jiao Lan4 He Ying1 ' target='_blank'>2 Zhai Fulin1 ' target='_blank'>2 Ou Lifang1 ' target='_blank'>2 |
| |
| Affiliation: | 1.Laboratory for Regenerative Medicine of Nanhua University，Hunan Chenzhou 423000，China;2.Department of Oncology；3.Department of Pharmacy,the First People's Hospital of Chenzhou,Hunan Chenzhou 423000,China;4.Department of Emergency,the First Affiliated Hospital of Nanhua University,Hunan Hengyang 421001,China. |
| |
| Abstract: | Objective:To evaluate the safety and therapeutic effect of dendritic cell(DC)-cytokine induced killer cells(CIKs) combined with chemotherapy and targeted therapy in treatment of advanced colon cancer patients.Methods:Thirty patients with advanced colon cancer patients(stage Ⅲ to Ⅳ) were treated by DC-CIK combined with chemotherapy and targeted therapy(avastin+oxaliplatin+capecitabine) and were taken as the combined treatment group.Another thirty advanced colon cancer patients treated with chemothrepy and targeted therapy(avastin+oxaliplatin+capecitabine) during the same period were taken as controls.The immune function,therapeutic effect,1-year survival,life quality,and side effects were compared between two groups.Furthermore,the safety and therapeutic effects of DC-CIK therapy were observed.Results:DC-CIK cells from advanced colon cancer patients were successfully induced,the ratios of CD3+CD8+ and CD3+CD56+ cells in DC-CIK cells were significantly increased after culture(P＜0.05).Compared with chemotherapy and targeted therapy group,the ratios of CD3+CD8+ and CD3+CD56+ cells in the peripheral blood after combined therapy were significantly increased after culture(P＜0.05).The combined therapy increased IFN-γ and IL-2 levels(P＜0.05).In the chemotherapy and targeted therapy group,the ratios of CD3+CD8+,CD3+CD4+,CD3-CD56+ cells and IFN-γ,IL-2 levels were decreased after culture(P＞0.05).The disease control rate(DCR) of combined therapy group was higher than that in chemotherapy and targeted therapy group(86% vs 60%,P＜0.01);The 1-year survival rates of combined therapy group and chemotherapy and targeted therapy group were 62% and 56% respectively(P＞0.05).The combined therapy group had less side effects(including bone marrow suppression,nausea and vomitting,and peripheral nerve toxicity) compared with the control chemotherapy and targeted therapy group.Conclusion:Treatment with DC-CIK cells combined with chemotherapy and targeted therapy is safe and effective for advanced colon cancer,and it can also improved the remission rate,survival and quality of life of advanced colon cancer patients. |
| |
| Keywords: | DC-CIK advanced colon cancer adoptive immune cell therapy targeted therapy chemotherapy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
|
